These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 15757457)

  • 1. Interrupting highly active antiretroviral therapy in patients with HIV.
    Ananworanich J; Hirschel B
    Expert Rev Anti Infect Ther; 2005 Feb; 3(1):51-60. PubMed ID: 15757457
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Structured treatment interruption in HIV infection.
    Benson CA
    AIDS Read; 2001 Feb; 11(2):99-102. PubMed ID: 11279889
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Structured treatment interruptions (STI) in chronic suppressed HIV infection in adults.
    Pai NP; Tulsky JP; Lawrence J; Colford JM; Reingold AL
    Cochrane Database Syst Rev; 2005 Oct; (4):CD005482. PubMed ID: 16235406
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Structured treatment interruptions in HIV/AIDS therapy.
    Lisziewicz J; Lori F
    Microbes Infect; 2002 Feb; 4(2):207-14. PubMed ID: 11880054
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Development of HIV with drug resistance after CD4 cell count-guided structured treatment interruptions in patients treated with highly active antiretroviral therapy after dual-nucleoside analogue treatment.
    Nuesch R; Ananworanich J; Sirivichayakul S; Ubolyam S; Siangphoe U; Hill A; Cooper D; Lange J; Phanuphak P; Ruxrungtham K
    Clin Infect Dis; 2005 Mar; 40(5):728-34. PubMed ID: 15714420
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HIV-1 viral rebound dynamics after a single treatment interruption depends on time of initiation of highly active antiretroviral therapy.
    Steingrover R; Pogány K; Fernandez Garcia E; Jurriaans S; Brinkman K; Schuitemaker H; Miedema F; Lange JM; Prins JM
    AIDS; 2008 Aug; 22(13):1583-8. PubMed ID: 18670217
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The virological and immunological consequences of structured treatment interruptions in chronic HIV-1 infection.
    García F; Plana M; Ortiz GM; Bonhoeffer S; Soriano A; Vidal C; Cruceta A; Arnedo M; Gil C; Pantaleo G; Pumarola T; Gallart T; Nixon DF; Miró JM; Gatell JM
    AIDS; 2001 Jun; 15(9):F29-40. PubMed ID: 11416735
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genetic characterization of rebounding human immunodeficiency virus type 1 in plasma during multiple interruptions of highly active antiretroviral therapy.
    Dybul M; Daucher M; Jensen MA; Hallahan CW; Chun TW; Belson M; Hidalgo B; Nickle DC; Yoder C; Metcalf JA; Davey RT; Ehler L; Kress-Rock D; Nies-Kraske E; Liu S; Mullins JI; Fauci AS
    J Virol; 2003 Mar; 77(5):3229-37. PubMed ID: 12584346
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biphasic decline of CD4 cell count during scheduled treatment interruptions.
    Fagard C; Bandelier CY; Ananworanich J; Le Braz M; Günthard H; Perneger T; García F; Hirschel B;
    AIDS; 2005 Mar; 19(4):439-41. PubMed ID: 15750398
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A prospective trial of structured treatment interruptions in human immunodeficiency virus infection.
    Fagard C; Oxenius A; Günthard H; Garcia F; Le Braz M; Mestre G; Battegay M; Furrer H; Vernazza P; Bernasconi E; Telenti A; Weber R; Leduc D; Yerly S; Price D; Dawson SJ; Klimkait T; Perneger TV; McLean A; Clotet B; Gatell JM; Perrin L; Plana M; Phillips R; Hirschel B;
    Arch Intern Med; 2003 May; 163(10):1220-6. PubMed ID: 12767960
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Structured interruptions of highly active antiretroviral therapy in cycles of 4 weeks off/12 weeks on therapy in children having a chronically undetectable viral load cause progressively smaller viral rebounds.
    Palacios GC; Sanchez LM; Briones E; Ramirez TJ; Castillo H; Rivera LG; Vazquez CA; Rodriguez-Padilla C; Holodniy M
    Int J Infect Dis; 2010 Jan; 14(1):e34-40. PubMed ID: 19467895
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antiretroviral therapy interruption guided by CD4 cell counts and plasma HIV-1 RNA levels in chronically HIV-1-infected patients.
    Ruiz L; Paredes R; Gómez G; Romeu J; Domingo P; Pérez-Alvarez N; Tambussi G; Llibre JM; Martínez-Picado J; Vidal F; Fumaz CR; Clotet B;
    AIDS; 2007 Jan; 21(2):169-78. PubMed ID: 17197807
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment interruption in HIV therapy: a SMART strategy?
    Jülg B; Goebel FD
    Infection; 2006 Jun; 34(3):186-8. PubMed ID: 16804667
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Extended antiretroviral treatment interruption in HIV-infected patients with long-term suppression of plasma HIV RNA.
    Achenbach CJ; Till M; Palella FJ; Knoll MD; Terp SM; Kalnins AU; Murphy RL
    HIV Med; 2005 Jan; 6(1):7-12. PubMed ID: 15670246
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Structured treatment interruptions for the management of HIV infection.
    Lori F; Lisziewicz J
    JAMA; 2001 Dec; 286(23):2981-7. PubMed ID: 11743839
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Approaches to interrupting HAART for the treatment of HIV infection. IAPAC sessions 2001, July 18-19, 2001 - Chicago.
    Dybul M;
    IAPAC Mon; 2001 Aug; 7(8):232-4. PubMed ID: 11708275
    [No Abstract]   [Full Text] [Related]  

  • 17. HIV-1 control after transient antiretroviral treatment initiated in primary infection: role of patient characteristics and effect of therapy.
    Goujard C; Girault I; Rouzioux C; Lécuroux C; Deveau C; Chaix ML; Jacomet C; Talamali A; Delfraissy JF; Venet A; Meyer L; Sinet M;
    Antivir Ther; 2012; 17(6):1001-9. PubMed ID: 22865544
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dynamics and evolution of HIV-1 during structured treatment interruptions.
    Frost SD
    AIDS Rev; 2002; 4(3):119-27. PubMed ID: 12416446
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CD4-guided scheduled treatment interruptions compared with continuous therapy for patients infected with HIV-1: results of the Staccato randomised trial.
    Ananworanich J; Gayet-Ageron A; Le Braz M; Prasithsirikul W; Chetchotisakd P; Kiertiburanakul S; Munsakul W; Raksakulkarn P; Tansuphasawasdikul S; Sirivichayakul S; Cavassini M; Karrer U; Genné D; Nüesch R; Vernazza P; Bernasconi E; Leduc D; Satchell C; Yerly S; Perrin L; Hill A; Perneger T; Phanuphak P; Furrer H; Cooper D; Ruxrungtham K; Hirschel B; ;
    Lancet; 2006 Aug; 368(9534):459-65. PubMed ID: 16890832
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunovirologic consequences and safety of short, non-structured interruptions of successful antiretroviral treatment.
    Sanchez R; Portilla J; Gimeno A; Boix V; Llopis C; Sanchez-Paya J; Merino E; de la Sen ML; Muñoz C; Reus S; Plazas J
    J Infect; 2007 Feb; 54(2):159-66. PubMed ID: 16690132
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.